Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H22N2O2.ClH |
Molecular Weight | 334.84 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)NCC(O)COC1=CC=CC2=C1C3=CC=CC=C3N2
InChI
InChIKey=DXYNUICMBSWZMR-UHFFFAOYSA-N
InChI=1S/C18H22N2O2.ClH/c1-12(2)19-10-13(21)11-22-17-9-5-8-16-18(17)14-6-3-4-7-15(14)20-16;/h3-9,12-13,19-21H,10-11H2,1-2H3;1H
Molecular Formula | C18H22N2O2 |
Molecular Weight | 298.3795 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Carazolol is a beta1/beta2 adrenoreceptor blocking agent. Activity and safety of the drug were evaluated in clinical trials that were conducted in healthy subjects and in patients suffering from either chronic bronchitis or asthma. The drug, however, was not developed for human use. Instead, carazolol is used in to reduce stress in animals during transportation. In veterinary medicine, carazolol is given by intramuscular injection to pigs is indicated in stress-inducing situations. In cattle, carazolol is intended to be used for the prevention of shipment stress caused by transportation and formation of new herds.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P08588 Gene ID: 153.0 Gene Symbol: ADRB1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/41147 |
0.15 nM [Ki] | ||
Target ID: P07550|||Q53GA6|||Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/41147 |
0.15 nM [Ki] |
PubMed
Title | Date | PubMed |
---|---|---|
Carazolol, an extremely potent beta-adrenergic blocker: binding to beta-receptors in brain membranes. | 1979 Jun 11 |
|
Carazolol: a potent, selective beta 3-adrenoceptor agonist. | 1995 Nov 30 |
|
Evidence for the binding of beta-adrenoceptor blockers to microsomal Na+/K+-ATPase in guinea pig heart preparations. | 2001 Jan |
|
Influence of supplemental magnesium, tryptophan, vitamin C, and vitamin E on stress responses of pigs to vibration. | 2005 Jul |
|
GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. | 2007 Nov 23 |
|
Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. | 2008 Aug 28 |
|
Structure of a beta1-adrenergic G-protein-coupled receptor. | 2008 Jul 24 |
|
Crystallizing thinking about the beta2-adrenergic receptor. | 2008 May |
|
On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. | 2008 May 22 |
|
Structural constraints for the binding of short peptides to claudin-4 revealed by surface plasmon resonance. | 2008 Nov 7 |
|
Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. | 2008 Oct 15 |
|
Rapid method for the determination of tranquilizers and a beta-blocker in porcine and bovine kidney by liquid chromatography with tandem mass spectrometry. | 2009 Apr 1 |
|
Chiral separation of beta-adrenergic blockers on CelluCoat column by HPLC. | 2009 Apr 30 |
|
X-ray structure breakthroughs in the GPCR transmembrane region. | 2009 Jul 1 |
|
Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. | 2010 Jan 7 |
|
Predicting drug-target interaction networks based on functional groups and biological features. | 2010 Mar 11 |
|
Cell distribution after intracoronary bone marrow stem cell delivery in damaged and undamaged myocardium: implications for clinical trials. | 2010 Mar 15 |
|
Forced unbinding of GPR17 ligands from wild type and R255I mutant receptor models through a computational approach. | 2010 Mar 16 |
|
Human health risk assessment of pharmaceuticals in water: issues and challenges ahead. | 2010 Nov |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:06:25 GMT 2023
by
admin
on
Sat Dec 16 11:06:25 GMT 2023
|
Record UNII |
4IVL5T473E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000029155
Created by
admin on Sat Dec 16 11:06:25 GMT 2023 , Edited by admin on Sat Dec 16 11:06:25 GMT 2023
|
PRIMARY | |||
|
305336
Created by
admin on Sat Dec 16 11:06:25 GMT 2023 , Edited by admin on Sat Dec 16 11:06:25 GMT 2023
|
PRIMARY | |||
|
4IVL5T473E
Created by
admin on Sat Dec 16 11:06:25 GMT 2023 , Edited by admin on Sat Dec 16 11:06:25 GMT 2023
|
PRIMARY | |||
|
20032198
Created by
admin on Sat Dec 16 11:06:25 GMT 2023 , Edited by admin on Sat Dec 16 11:06:25 GMT 2023
|
PRIMARY | |||
|
51997-43-4
Created by
admin on Sat Dec 16 11:06:25 GMT 2023 , Edited by admin on Sat Dec 16 11:06:25 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE |